title: No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis in advanced carcinoma of cervix.
abstract: 55 patients suffering from stage III or IV carcinoma of cervix were treated with two pulses of neo-adjuvant chemotherapy prior to radical radiotherapy. 51% (26/51) had a partial response. The initial response to chemotherapy is associated with significantly better long-term survival. The 3-year survival of chemotherapy responders is 62% against 21% for non-responders (P = 0.009 log-rank test). To detect possible differences in oncogene expression in biopsy specimens taken from responding and non-responding patients, paraffin-fixed material was immunocytochemically stained for the expression of the protein products of ras, c-myc and c-jun proto-oncogenes. The frequency of oncogene expression was ras 80.4%, c-myc 45.1% and c-jun 39.2%. There was no statistically significant association between oncogene expression, time to local recurrence or development of metastases or survival.
authors.affiliation: Beatson Oncology Centre, Western Infirmary, Glasgow, U.K.
authors.forename: R P
authors.initials: RP
authors.lastname: Symonds
authors.forename: T
authors.initials: T
authors.lastname: Habeshaw
authors.forename: J
authors.initials: J
authors.lastname: Paul
authors.forename: D J
authors.initials: DJ
authors.lastname: Kerr
authors.forename: A
authors.initials: A
authors.lastname: Darling
authors.forename: R A
authors.initials: RA
authors.lastname: Burnett
authors.forename: F
authors.initials: F
authors.lastname: Sotsiou
authors.forename: S
authors.initials: S
authors.lastname: Linardopoulos
authors.forename: D A
authors.initials: DA
authors.lastname: Spandidos
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016758:Genes, jun / Q000502:physiology*; D016259:Genes, myc / Q000502:physiology*; D011905:Genes, ras / Q000502:physiology*; D006801:Humans; D008875:Middle Aged; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality